๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Radiation therapy in the treatment of aggressive fibromatoses (desmoid tumors)

โœ Scribed by Krystyna D. Kiel; Herman D. Suit


Publisher
John Wiley and Sons
Year
1984
Tongue
English
Weight
412 KB
Volume
54
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Radiation therapy in the treatment of ma
โœ David Elkon; Martin Colman; Frank R. Hendrickson ๐Ÿ“‚ Article ๐Ÿ“… 1978 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 370 KB ๐Ÿ‘ 2 views

A retrospective analysis of 52 patients with malignant salivary gland tumors is reported. Seventeen patients received early postoperative radiation therapy and 16 (94%) were free of local or regional disease 2-14 years following initiation of therapy, although 14 were considered at high risk of deve

Surgery versus radiation therapy for pat
โœ Joost J. Nuyttens; Philip F. Rust; Charles R. Thomas Jr.; Andrew T. Turrisi III ๐Ÿ“‚ Article ๐Ÿ“… 2000 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 78 KB ๐Ÿ‘ 1 views

## BACKGROUND. Desmoid tumors (aggressive fibromatoses) are benign neoplasms with high rates of recurrence after surgery. Radiotherapy is sometimes reported to prevent recurrences, but not in all studies. In order to evaluate the effect of radiation, comparative analysis was performed. ## METHODS.

Superfractionation radiation therapy in
โœ Kyu H. Shin; Paul J. Muller; Peter H. S. Geggie ๐Ÿ“‚ Article ๐Ÿ“… 1983 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 370 KB ๐Ÿ‘ 2 views

Superfractionation (SF) radiation therapy is the administration of three fractions per day. We have assessed the effect of SF in a prospective randomized clinical study of malignant astrocytomas from July 1978 to December 1980. Thirty-five patients were randomized to SF (4000 rad in 45 fractions in

Role of radiation therapy in the treatme
โœ Roy R. Deffebach; Theodore L. Phillips ๐Ÿ“‚ Article ๐Ÿ“… 1972 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 438 KB ๐Ÿ‘ 2 views

One hundred and one cases of early and late supraglottic tumors covering a period of 22 years have been evaluated. The early stages, without lymph node metastasis, show a 75% 2-year control and a 50% 5-year survival. T h e local control rate is 75% in those patients treated at a dose equivalent to m